AZR

Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Contact lens, CLD, Meibomian gland dysfunction, Safety, Gland, Lens, Eyelid, Irritation, AZR, Dry, Patient, FDA, Ophthalmic, Fluorescein, Contact, MGD, MGS, Pain, Quality of life, Telescopic sight, Azura

This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.

Key Points: 
  • This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.
  • “MGD is the root cause of many downstream ocular surface conditions that impact quality of life and vision for patients, including Contact Lens Discomfort.
  • This leads to several downstream ocular surface symptoms including dryness, pain, irritation, reduced quality of vision, and Contact Lens Discomfort.
  • “MGD is one of the causes of Contact Lens Discomfort, and many patients give up on wearing contact lenses altogether due to the irritation they experience.

Diamond Kinetics and Marucci Unveil First-Of-Its-Kind Fully Integrated Smart Bat

Retrieved on: 
Tuesday, November 28, 2023
Diamond, ID, Entrepreneurship, Baseball, AZR, Marucci Sports, Tiger, Marucci, Partnership, CATX, Apple, College World Series, Athlete, Francisco Lindor, USSSA, IOS, Sports equipment, Electric battery

and PITTSBURGH, Nov. 28, 2023 /PRNewswire/ -- Two of the most innovative companies in baseball, Marucci and Diamond Kinetics (DK), unveiled the Marucci CATX Smart, the first smart bat with an integrated sensor approved by USSSA for in-game use, setting a new standard for smart baseball equipment.

Key Points: 
  • and PITTSBURGH, Nov. 28, 2023 /PRNewswire/ -- Two of the most innovative companies in baseball, Marucci and Diamond Kinetics (DK), unveiled the Marucci CATX Smart, the first smart bat with an integrated sensor approved by USSSA for in-game use, setting a new standard for smart baseball equipment.
  • The Marucci CATX Smart is the first smart bat to be approved for in-game use as part of the United States Specialty Sports Association (USSSA) bat standard, so any tournament, league, or organization that requires the USSSA stamp will allow this bat in-game play.
  • "We can't wait for athletes to get their hands on the new Marucci CATX Smart," said Kurt Ainsworth, Co-Founder and CEO of Marucci Sports.
  • "The Marucci CATX Smart is a direct lens into the future of the game of baseball," said CJ Handron, Co-Founder and CEO of Diamond Kinetics.

EQS-News: Befesa S.A.: Befesa continues to deliver strong results with 9M’22 up 20% yoy and confirms FY guidance towards lower end

Retrieved on: 
Friday, October 28, 2022
EBITDA, Hazardous waste, Acquisition, Growth, Capital market, Environment, Zinc, Frankfurt Stock Exchange, AZR, SGGP, Steel, Time, LTM, Steel Dust, Yoy, SHG, Plant, Silviculture, Renewable energy, Q3, Abengoa

Adjusted EBITDA for Q3 stood at 45.9m, compared to 42.7m in the same quarter last year, an increase of 7.6% YoY.

Key Points: 
  • Adjusted EBITDA for Q3 stood at 45.9m, compared to 42.7m in the same quarter last year, an increase of 7.6% YoY.
  • Zinc market prices averaged at 3,245/t in Q3 (up 28% YoY), aluminium alloy prices at 2,327/t (up 16% YoY), offsetting inflation, primarily energy, for the most part.
  • In September, Befesa acquired the remaining 93% stake in the zinc refining asset in the US from former AZR owners.
  • Befesa already owned 7% of the refining asset, as part of the acquisition of American Zinc Recycling (AZR) which closed in August 2021.

Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

Retrieved on: 
Wednesday, September 28, 2022
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Optical, Science, Therapy, Safety, Trial of the century, Twitter, FDA, Food, OSDI, AZR, Duane syndrome, IND, LinkedIn, Population, MGS, CLD, Exocrine gland, DED, Selenium disulfide, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, CEO, M. A, Corneal ulcers in animals, Severe cognitive impairment, M. B, Diagnosis, Meibomian gland, Drug development, Investigational New Drug, Milner, Classification, Luchs, Ophthalmic drug administration, MGD, Pharmaceutical industry, Telescopic sight, Medical device, Azura, Ophthalmology, Amit Majmudar

Meibomian Gland Dysfunction is the leading cause of Dry Eye Disease and Contact Lens Discomfort impacting millions of people in the U.S. alone, said Marc Gleeson, CEO of Azura Ophthalmics.

Key Points: 
  • Meibomian Gland Dysfunction is the leading cause of Dry Eye Disease and Contact Lens Discomfort impacting millions of people in the U.S. alone, said Marc Gleeson, CEO of Azura Ophthalmics.
  • Azura is currently conducting a multi-center, double-masked, vehicle-controlled Phase 2b study that will evaluate the safety and efficacy of AZR-MD-001 in patients with MGD.
  • The ongoing study builds upon previous findings from a successful Phase 2a clinical trial evaluating AZR-MD-001 in the same patient population.
  • Meibomian Gland Dysfunction (MGD) is a chronic and progressive condition associated with blockage of the meibomian glands and alteration in the quality of expressed meibum.

DGAP-News: Befesa S.A.: Befesa continues to deliver with 25% yoy EBITDA growth and €118m in H1, despite volatile market environment

Retrieved on: 
Thursday, July 28, 2022
Zinc, FMB, AZR, Acquisition, LME, Global, Taxonomy, Capital market, Hazardous waste, Line of credit, S&P, CO2, TC, Steel, COVID, SGGP, Steel Dust, RCF, ESG, Growth, EBITDA, Security (finance), Oil, Silviculture, Renewable energy, Abengoa, EU, H1

Befesa S.A.: Befesa continues to deliver with 25% yoy EBITDA growth and 118m in H1, despite volatile market environment

Key Points: 
  • Befesa S.A.: Befesa continues to deliver with 25% yoy EBITDA growth and 118m in H1, despite volatile market environment
    The issuer is solely responsible for the content of this announcement.
  • Befesa delivered adjusted EBITDA of 118.0m in H122 (H121: 94.1m) and 56.9m in Q222 (Q221: 45.3m), representing an increase of 25% and 26% yoy respectively.
  • The yoy higher base metal prices offset the energy inflation and higher zinc treatment charges (TC) at $230/t.
  • Javier Molina, Executive Chair of Befesa, commented: In H1, we continued to deliver 25% yoy EBITDA growth in a challenging market environment.

DGAP-News: Befesa S.A.: Befesa delivers all-time high FY EBITDA of €198m (+56% yoy)

Retrieved on: 
Thursday, February 24, 2022
ESG, Hazardous waste, AZR, CO2, RCF, Hand, Company, EPS, Acquisition, EAF, Zinc, SPL, CEO, Waelz process, EBITDA, Line of credit, Oil, Real estate, Lithium, Iron ore, Abengoa

Adjusted EBITDA for Q4 came in at 60.8m, compared to 42.4m in the same quarter last year, representing an increase of 43%.

Key Points: 
  • Adjusted EBITDA for Q4 came in at 60.8m, compared to 42.4m in the same quarter last year, representing an increase of 43%.
  • Full-year growth was even stronger, as Befesa achieved 197.6 in 2021, up 71m or 56% compared to FY 2020 and 24% more than the pre-pandemic FY 2019 figure of 159.6m.
  • In 2021, Befesa's operating cash flow improved by 27% yoy to a new record level of 117.9m (FY 2020: 92.5m).
  • Together with the entirely undrawn Revolving Credit Facility (RCF) of 75.0m, Befesa has a robust financial position of c. 300m liquidity.

DGAP-News: Befesa S.A.: Befesa reports record level 9M EBITDA of €137m up 62% YoY

Retrieved on: 
Thursday, October 28, 2021
AZR, EBITDA, SDAX, Recycling, IPO, SPL, Q3, Hand, MDAX, Company, Steel Dust, CEO, Growth, Environment, Steel, Acquisition, Yoy, FY, Lithium, Oil

Adjusted EBITDA for Q3 stood at 42.7m, compared to 29.3m in the same quarter last year, an increase of 46%.

Key Points: 
  • Adjusted EBITDA for Q3 stood at 42.7m, compared to 29.3m in the same quarter last year, an increase of 46%.
  • Year-to-date growth was even stronger, as Befesa achieved 136.8 in the first nine months, up 52m or 62% compared to 9M 2020 and 17% more than the pre-pandemic 9M 2019 figure of 117.1m.
  • The YoY positive earnings development in 9M was mainly driven by strong base metal prices and good volume performance.
  • Befesa renamed its acquired US operations to Befesa Zinc US and appointed Rodrigo Daud as CEO and president.

American Zinc Recycling LLC Closes Sale on Recycling Business and Establishes American Zinc Products Joint Venture

Retrieved on: 
Tuesday, August 17, 2021
Chemicals, Plastics, Other Manufacturing, Manufacturing, Steel, Jarden Zinc Products, LLC, Nickel, Executive, Acquisition, Continuity, Dust, Leadership, CGG, EAF, Lead, AZR, CFO, Special, Achievement, Zinc, Recycling, COO, CEO, Sale, Â, SHG, Management

American Zinc Recycling LLC (AZR LLC) announced the closing of the transaction that was previously announced on June 16, 2021, pursuant to which Befesa S.A., through a US subsidiary (Befesa), has purchased all of the stock of American Zinc Recycling Corp. (AZR Corp.) and obtained a minority position in American Zinc Products LLC (AZP).

Key Points: 
  • American Zinc Recycling LLC (AZR LLC) announced the closing of the transaction that was previously announced on June 16, 2021, pursuant to which Befesa S.A., through a US subsidiary (Befesa), has purchased all of the stock of American Zinc Recycling Corp. (AZR Corp.) and obtained a minority position in American Zinc Products LLC (AZP).
  • AZR LLC will continue to own all the equity interests in its subsidiary The International Metals Reclamation Company, LLC (INMETCO).
  • Mr. Griffin commented, The entire team at AZR LLC brought us to this pivotal point in the companys success.
  • As part of this transaction, AZR LLC will be renamed Metals Recovery Holdings LLC (AZR LLC as so renamed and after giving effect to Befesas acquisition of AZR Corp., Metals Recovery Holdings LLC).